Clinical trials: Community-Acquired Infection
Community-acquired Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in hospitalized subjects with sCAP on invasive mechanical…
- Trial name
- ESsCAPE (NCT05722938)
- Testing
- Trimodulin
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 590 people
- Sponsor
- Biotest
Community Acquired Infections
Tigecycline In-Vitro Surveillance Study In Taiwan
In-vitro surveillance study of tigecycline (Tygacil) in Taiwan.
- Trial name
- NCT00488397
- Testing
- In-vitro testing
- Where
- China
- Volunteers
- 7,902 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Infection, Community-Acquired, Communicable Disease
Infection Detection by Breath Analysis
The purpose of this feasibility study is to test a device which analyzes breath and may allow doctors and health professionals to immediately determine if an ill patient has a specific type of bacterial infection.
- Conditions
- Infection, Community-Acquired, Communicable Disease, Respiratory Infection
- Trial name
- NCT02981550
- Sponsor
- BreathTec Biomedical Inc.
Abdominal Abscess
Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections
The primary objective of this study is to compare the safety and efficacy of an experimental antibiotic to a marketed antibiotic in the treatment of Chinese subjects with complicated intra-abdominal infections. <br />
- Trial name
- NCT00136201
- Testing
- tigecycline
- Where
- 11 sites in China
- Volunteers
- 200 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumonia, Bacterial
The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)
Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet been approved in Japan.
- Trial name
- NCT01189487
- Testing
- ampicillin sodium/sulbactam sodium
- Where
- 22 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Pfizer
Covid19, Community-Acquired Respiratory Tract Infection
Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19
Solving the problem of detecting asymptomatic carriers who can transmit infection is key to protecting vulnerable residents of nursing homes and assisted living facilities, to protecting frontline workers who care for them, and…
- Trial name
- NCT04548895
- Testing
- Observational measurement of biometric data. No change to health care provided.
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Health Stream Analytics, LLC
Pneumonia, Community-Acquired, Bacterial Pneumonia
Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)
The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP).
- Trial name
- NCT06804096
- Testing
- Faropenem, Co-amoxiclav, Clarithromycin 500 mg
- Where
- 2 sites in Bangladesh
- Volunteers
- 129 people
- Sponsor
- Dr. Md. Alimur Reza
Pneumonia, Bacterial, Community-Acquired Infections
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with pneumonia.
- Conditions
- Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
- Trial name
- NCT01110421
- Testing
- Cefepime, Doripenem, Amoxicillin/clavulanate potassium
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Respiratory Tract Infections, Chronic Bronchitis
KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections
The purpose of this study is to determine if 1 course of antibiotic treatment with telithromycin is superior to azithromycin in the treatment of lower respiratory tract infections (LRTIs), acute exacerbations of chronic…
- Conditions
- Respiratory Tract Infections, Chronic Bronchitis, Pneumonia
- Trial name
- KEYS (NCT00132951)
- Testing
- Telithromycin, Azithromycin
- Where
- 2 sites in United States, Canada
- Volunteers
- 2,051 people
- Sponsor
- Sanofi
Pneumonia
Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients With CAP
1. This study will test the safety and efficacy of TG-873870 (Nemonoxacin) compared with Levofloxacin in adult patients with Community-Aquired Pneumonia (CAP) 2.
- Trial name
- NCT01529476
- Testing
- Levofloxacin, Nemonoxacin
- Where
- 57 sites in China, Taiwan
- Volunteers
- 540 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Pneumonia
Community-Acquired Pneumonia (CAP) Surveillance
Prospective, non-interventional, multi-center study. 7 investigative centers will involved in China. Around 560 CAP outpatients or inpatients will be screened until 56 M. pneumoniae isolates collected.
- Trial name
- NCT01416506
- Testing
- No Drug
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Bayer
Community-Acquired Pneumonia (CAP)
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens.
- Trial name
- NCT00035347
- Testing
- IV azithromycin, ceftriaxone, oral azithromycin
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Sepsis
To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)
To collect clinical response data with the use of ertapenem in community acquired sepsis.
- Trial name
- NCT00397956
- Testing
- MK0826, ertapenem sodium / Duration of Treatment: 14 Days
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
Pneumonia
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
The purpose of this study is to learn about how well the 20-valent pneumococcal conjugate vaccine (20vPnC) works against radiologically-confirmed community-acquired pneumonia (RAD+CAP) due to the 7 new serotypes (types of a…
- Trial name
- NCT05452941
- Testing
- Diagnostic test on urine samples
- Where
- 54 sites in United States, Israel and 1 more
- Volunteers
- 12,500 people
- Sponsor
- Pfizer
Infections, Bacterial
A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS
The purpose of this study is to evaluate the pharmacokinetics, safety or tolerability through treatment emergent adverse event (TEAE) and to explore primary and secondary clinical response of treatment with Augmentin ES in…
- Trial name
- NCT05340257
- Testing
- Augmentin ES
- Where
- 2 sites in Brazil
- Sponsor
- GlaxoSmithKline
Community-acquired Pneumonia, Bacterial Pneumonia
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
- Trial name
- NCT04779242
- Testing
- Omadacycline, Moxifloxacin
- Where
- 55 sites in Bulgaria, Croatia and 6 more
- Volunteers
- 670 people
- Sponsor
- Paratek Pharmaceuticals Inc
Complicated Skin and Skin Structure Infections, Complicated Intra-abdominal Infections
Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment
The primary objective of this study is to identify any changes on the safety profile of adverse events and serious adverse events.
- Conditions
- Complicated Skin and Skin Structure Infections, Complicated Intra-abdominal Infections, Community-Acquired Bacterial Pneumonia
- Trial name
- NCT01072539
- Testing
- tigecycline
- Where
- 36 sites in South Korea
- Volunteers
- 3,172 people
- Sponsor
- Pfizer
Community-Acquired Bacterial Pneumonia, Lung Infection of Individual Not Recently Hospitalized
A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
This purpose of this study is to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia.
- Trial name
- NCT01371838
- Testing
- Ceftaroline, Ceftriaxone
- Where
- 43 sites in China, India and 3 more
- Volunteers
- 848 people
- Sponsor
- Pfizer
Community Acquired Pneumonia
A P3 Comparator Trial in Community Acquired Bacterial Pneumonia
This study will be a double-blind, randomized, multicenter trial to assess the safety and efficacy of a single 1500 mg IV dose of dalbavancin plus a single 500 mg IV dose of azithromycin in comparison to an approved antibiotic…
- Trial name
- NCT02269644
- Testing
- Dalbavancin, Linezolid, Azithromycin
- Where
- United States
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc